SCHEMBL900266

SCHEMBL900266

CNC(=O)c1c(N2CCN(C(=O)C=CC(F)(F)F)CC2)cc(C)nc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 5/20 0.35
HTT P42858 1/20 0.35
NCF1 P14598 1/20 0.35
CSF1R P07333 1/20 0.34
AR P10275 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
RBP4 P02753 2/20 0.33
GAA P10253 2/20 0.33
PHGDH O43175 3/20 0.32
KDM4E B2RXH2 1/20 0.32
USP2 O75604 1/20 0.32
HSD17B10 Q99714 1/20 0.32
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32
FGFR4 P22455 1/20 0.32
FGFR3 P22607 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL900265 1.00 MEN1 (0.43) MEN1KMT2AALDH1A1HTTNCF1
SCHEMBL899803 0.74 NCF1 (0.46) NCF1HPGDKDM4EUSP2HSD17B10
SCHEMBL16566592 0.68 SLC6A7 (0.52) MEN1KMT2AALDH1A1HTTMAPT
SCHEMBL15295889 0.68 SLC6A7 (0.52) MEN1KMT2AALDH1A1HTTMAPT
SCHEMBL15286927 0.68 KMT2A (0.43) MEN1KMT2AALDH1A1HTTMAPT
SCHEMBL16566786 0.68 KMT2A (0.43) MEN1KMT2AALDH1A1HTTMAPT
SCHEMBL15286379 0.67 ALDH1A1 (0.36) MEN1KMT2AALDH1A1HTTAR
SCHEMBL15286382 0.67 ALDH1A1 (0.36) MEN1KMT2AALDH1A1HTTAR
SCHEMBL16566656 0.66 MAPT (0.44) MEN1KMT2AALDH1A1HTTMAPT
SCHEMBL16566655 0.66 MAPT (0.44) MEN1KMT2AALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2621923-B1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES INTERVET INT BV (NL) 2017-03-29 EP disclosed
US-8883791-B2 N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases INTERVET INC. (US) 2014-11-11 US disclosed
US-20130203768-A1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES INTERVET INC. 2013-08-08 US disclosed
EP-2621923-A1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES Intervet International B.V. (NL) 2013-08-07 EP disclosed
WO-2012041872-A1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES INTERVET INTERNATIONAL B.V. (NL) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203768-A1 N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES PIGO, HNMT, PIGS MEN1 1483/4885KMT2A 2910/4885ALDH1A1 1547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.